> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Anoro Ellipta
- URL: https://www.fdaweb.com/review-period-set-for-anoro-ellipta/
- Published: 2016-03-01T12:00:00.000Z
- Updated: 2026-09-15T02:39:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134930

*Federal Register* Notice: FDA has determined the regulatory review period for Glaxo’s Anoro Ellipta (umeclidinium/vilanterol) is 1,589 days for extending a patent which claims the human drug product. It is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-03-01/pdf/2016-04370.pdf?ref=fdaweb.com)